• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Incyte Corp. (Amendment)

    2/14/23 2:03:59 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email
    SC 13G/A 1 d650496dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 1)*

     

     

    INCYTE CORPORATION

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    45337C102

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 45337C102    13G    PAGE 2 OF 4 PAGES

     

      1   

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Dodge & Cox    94-1441976

      2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  ☐        (b)  ☐

     

    N/A

      3   

      SEC USE ONLY

     

      4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    California - U.S.A.

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

          5     

    SOLE VOTING POWER

     

    18,209,985

          6     

    SHARED VOTING POWER

     

    0

          7     

    SOLE DISPOSITIVE POWER

     

    19,362,935

          8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    19,362,935

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

    N/A

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    8.7%

    12   

    TYPE OF REPORTING PERSON*

     

    IA


    Item 1(a)

    Name of Issuer:

    INCYTE CORPORATION

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    1801 Augustine Cut-Off

    Wilmington, Delaware 19803

     

    Item 2(a)

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b)

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c)

    Citizenship:

    California - U.S.A.

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock

     

    Item 2(e)

    CUSIP Number:

    45337C102

     

    Item 3

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

    (e) ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    19,362,935

     

      (b)

    Percent of Class:

    8.7%


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    18,209,985

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of:

    19,362,935

     

      (iv)

    shared power to dispose or to direct the disposition of:

    0

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, INCYTE CORPORATION.

    Dodge & Cox Stock Fund, an investment company registered under the Investment Company Act of 1940, has an interest of 12,002,300, or 5.4%, of the class of securities reported herein.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023            

     

    DODGE & COX
    By:  

    /S/ Katherine M. Primas

    Name:   Katherine M. Primas
    Title:   Chief Compliance Officer
    Get the next $INCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    5/23/2024$55.00Hold
    Deutsche Bank
    More analyst ratings

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

      Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapy Patients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable lo

      5/15/25 2:30:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Incyte (NASDAQ:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,413 shares of the Company's common stock and stock option awards to purchase an aggregate of 8,951 shares of the Company's common stock to 60 new employees. The awards were made under the Company's 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of May 1, 2025, and were approved by the compensation committee of the Company's board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU vests as to 25% of the shares subject to the

      5/7/25 4:30:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte to Present at Upcoming Investor Conference

      Incyte (NASDAQ:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in

      5/1/25 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & General Manager US Flannelly Barry P was granted 26,135 shares, increasing direct ownership by 78% to 59,702 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      4/3/25 4:52:43 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP, GMAPPS Iyengar Vijay K was granted 22,141 shares, increasing direct ownership by 72% to 52,799 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      4/3/25 4:52:14 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP, Head of Tech. Operations Morrissey Michael James was granted 4,649 shares, increasing direct ownership by 6% to 86,164 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      4/3/25 4:51:26 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Incyte downgraded by Guggenheim

      Guggenheim downgraded Incyte from Buy to Neutral

      3/18/25 7:52:49 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by William Blair

      William Blair downgraded Incyte from Outperform to Mkt Perform

      3/18/25 7:52:29 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • UBS initiated coverage on Incyte with a new price target

      UBS initiated coverage of Incyte with a rating of Neutral and set a new price target of $77.00

      12/17/24 9:34:33 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

      Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr

      6/12/23 4:01:00 PM ET
      $GLPG
      $INCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Incyte Names New Member to Its Board of Directors

      Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company

      10/4/22 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

      1/25/22 4:30:00 PM ET
      $INCY
      $MRUS
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Incyte Corp.

      SC 13G - INCYTE CORP (0000879169) (Subject)

      10/17/24 9:39:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Incyte Corp.

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      6/14/24 6:23:05 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      5/13/24 6:06:33 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

      9/28/21 5:20:01 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

      9/23/21 5:11:12 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for OPZELURA issued to INCYTE CORP

      Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      9/22/21 11:16:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Financials

    Live finance-specific insights

    See more
    • Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

      – Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million – Opzelura® (ruxolitinib) cream net product revenues of $119 million in Q1'25 (+38% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $14 million in the first two months of U.S. launch demonstrating strong commercial execution and high patient need – New, 18-week data from ongoing Phase 3 study of povorcitinib in hidradenitis suppurativa (HS) demonstrates

      4/29/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte to Report First Quarter Financial Results

      Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13753168 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-74

      4/10/25 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

      - Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested - Favorable safety profile, with no safety concerns - Data will support planned regulatory submission for povorcitinib in hidradenitis suppurativa (HS) worldwide - Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET Incyte (NASDAQ:INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Both

      3/17/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    SEC Filings

    See more
    • Incyte Corp. filed SEC Form 8-K: Other Events

      8-K - INCYTE CORP (0000879169) (Filer)

      5/14/25 7:53:36 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by Incyte Corp.

      DEFA14A - INCYTE CORP (0000879169) (Filer)

      4/29/25 4:08:32 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEF 14A filed by Incyte Corp.

      DEF 14A - INCYTE CORP (0000879169) (Filer)

      4/29/25 4:06:08 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care